The Effect of Nasal Continuous Positive Airway Pressure Treatment on PTSD Symptoms. (PTSD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01512771|
Recruitment Status : Completed
First Posted : January 19, 2012
Last Update Posted : September 25, 2014
|Condition or disease||Intervention/treatment|
|Post Traumatic Stress Disorder Anxiety Nightmares Unrefreshed Sleep||Other: CPAP|
Design: This is a pilot study to study the effect of nasal CPAP on the symptoms of PTSD in veterans.
Veterans with PTSD will be recruited from the Northport VAMC PTSD unit. The ACOS/Mental Health will refer patients that meet inclusion criteria and do not have an impaired decision making capacity. Subjects will be screened for decision-making capacity by their treating psychiatrist as part of their clinical assessment upon admission to the PTSD unit.
This will be a prospective, randomized, controlled interventional trial:
- Participants will undergo a routine clinical sleep study at the PTSD unit (using a portable polysomnographic recording unit). or undergo a routine clinical polysomnography to diagnose sleep disordered breathing
Participants who demonstrate SDB will be randomized into two groups based upon their body mass index
- Group A: BMI < 30 kg/m2
- Group B: BMI > 30 kg/m2 The reason for these two arms is to study the effect of nasal CPAP upon PTSD symptoms in veterans with a high prevalence of sleep apnea ( BMI above 30 kg/m2) and in veterans with predominantly snoring (BMI below 30 kg/m2).
Each group will then be randomized into two sub-groups regarding treatment.
- Treatment group receives an automated CPAP unit to use during sleep for 6 weeks in conjunction with their usual care in the PTSD unit (psychotherapy).
- Control group receives the usual care that is provided in the PTSD unit for 6 weeks (change in medications will exclude the subject from the study), if any participant in the control group would like to try nasal CPAP, then he will be crossed over to use an automated CPAP unit during sleep for his second 6 weeks in the PTSD unit together with usual care.
All participants will fill out the following questionnaires at baseline and after 6 weeks. (Those in the control group who have been crossed-over to nasal CPAP will also fill out a set of questionnaire at 12 weeks).
- PTSD checklist-military version (anxiety)
- MASQ anxious arousal subscale (anxiety)
- Insomnia Severity Index (insomnia)
- The alcohol craving questionnaire (with an alcohol history during the intake) The changes in patient's reported outcomes will be compared before and after CPAP treatment and psychotherapy alone
|Study Type :||Observational|
|Actual Enrollment :||18 participants|
|Official Title:||The Effect of Nasal Continuous Positive Airway Pressure (Nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms.|
|Study Start Date :||March 2010|
|Actual Primary Completion Date :||August 2014|
|Actual Study Completion Date :||August 2014|
- Other: CPAP
6 weeks of CPAP
- The Effect of nasal Continuous Positive Airway Pressure (nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms. [ Time Frame: six weeks of nasal CPAP ]A comparison of the effectiveness of six weeks of nasal CPAP plus usual care to usual care alone at decreasing the symptoms of PTSD (anxiety, insomnia and alcohol craving) among veterans with PTSD and SDB
- The Effect of nasal Continuous Positive Airway Pressure (nasal CPAP) Treatment on Post Traumatic Stress Disorder (PTSD) Symptoms. [ Time Frame: 6 weeks of nasal CPAP ]A comparison of the change in symptoms to the change in the total of sleep stage shifts during sleep for all patients with PTSD and SDB participating in the study.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01512771
|United States, New York|
|PTSD unit at Northport VAMC|
|Northport, New York, United States, 11768|
|Principal Investigator:||Mohammad Amin, MD||Northport VAMC|